From: In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis
Tolvaptan – Initial usage policy |
ᅟ1) Confirm SIADH (See Fig. 1a) AND |
ᅟ2) Na <125 despite 48 h fluid restriction at 750 ml/24 h or |
ᅟ3) Na <125 and falling despite 24 h fluid restriction @ 750 ml/24 h or |
ᅟ4) Symptoms/risks associated with 2) or 3) awaiting for Chemotherapy |
At initiation of Tolvaptan |
ᅟ1) Stop fluid restriction (allow patient to drink when thirsty) |
ᅟ1) Monitor Na levels 6hrly for 36 h then 12hrly |
ᅟ1) Review Tolvaptan use at 3, 6 and 9 days |
ᅟ1) If Na rises by >6 at 6 h, >8 mmol/L in 12 h, >12 mmol/L in 24 h or >18 in 48 h OR if Na >126, STOP Tolvaptan and continue to monitor Na 12hrly for 36 h – Consider 5% Dextrose. |